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ABSTRACT 
The pulse frequency of hypothalamic GnRH secretion increases at the onset of puberty. In rodents 
and primates, this process involves facilitatory and inhibitory effects mediated through 
hypothalamic N-methyl-D-aspartic acid (NMDA) and γ-aminobutyric acid (GABA) receptors, 
respectively. Precocious puberty was observed in an 11-month-old girl with nonketotic 
hyperglycinemia. This was thought to result from the effect of high concentrations of glycine (112 
µmol/L in cerebrospinal fluid; normal, 3–12) acting on NMDA receptors as a coagonist of glutamate. 
Regression of pubertal development during anticonvulsive treatment with GABA agonists 
(loreclezole and vigabatrin) suggested that the stimulatory effects of glycine could be overcome by 
GABA receptor-mediated inhibition. These two hypotheses were tested in the in vitro model of the 
explanted hypothalamus from infantile (15-day-old) male rats. Glycine concentrations of 1–10 
µmol/L increased the pulse frequency of GnRH secretion. This acceleration was prevented by 7-
chlorokynurenic acid, a glycine antagonist at the NMDA receptor complex, and by the GABA agonist 
loreclezole. In addition, loreclezole and vigabatrin suppressed the developmental increase in the 
frequency of pulsatile GnRH secretion. The observation of precocious puberty in an infant with 
hyperglycinemia followed by pubertal regression during GABA agonist therapy and the in vitro 
findings in hypothalamic explants suggest that stimulatory inputs mediated through NMDA 
receptors and inhibitory inputs through GABA receptors are involved in the initiation of puberty.
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In many species, including man, the hypothalamus has the capacity to secrete GnRH in a pulsatile 
manner. The onset of puberty is preceded by an increase in the pulse frequency of GnRH secretion, 
as shown in portal blood of female monkeys (1) or in the incubation medium of hypothalamic 
explants of male rats (2, 3). In children and adolescents, a similar process is evidenced indirectly 
through sequential LH measurements in peripheral blood (4, 5). 
The gonadotropic axis is known to be active in the human fetus and infant before the long 
quiescent period preceding onset of puberty (6). Precocious puberty is observed after central 
nervous system (CNS) irradiation (7, 8) and following experimental disconnection or lesion of 
particular hypothalamic areas (9, 10). These data suggest that a hypothalamic facilitatory 
mechanism is operational prepubertally, whereas an inhibitory or restraining mechanism is 
superimposed. The facilitatory mechanism may involve a subtype of glutamate receptors that 
selectively bind the agonist N-methyl-D-aspartate (NMDA), because early onset of puberty is caused 
by chronic intermittent administration of NMDA to infantile female rats (11) or juvenile male 
monkeys (12). Using pharmacological and antisense strategies in vitro, we showed recently that in 
the infantile rat hypothalamus, the drive of pulsatile GnRH secretion via NMDA receptors was 
restrained by a γ-aminobutyric acidA (GABAA) receptor-mediated inhibition (13). This GABA-ergic 
inhibition showed a marked reduction at the onset of puberty (14), confirming data obtained 
previously in the juvenile female monkey (15). 
In man, no evidence of NMDA receptor involvement in the neuroendocrine regulation of 
gonadotropin secretion has been provided to date. Scarce data on the inhibition of gonadotropin 
secretion by antiepileptic drugs such as valproic acid, a GABA agonist (16), suggest a possible 
inhibitory role of GABA receptors (17–19). In this preliminary report, precocious puberty in a female 
infant with nonketotic hyperglycinemia (NKH) was postulated to be related to glycine-mediated 
NMDA receptor stimulation. In addition, regression of pubertal development was observed during 
therapy with antiepileptic GABA agonists and was proposed to be related to GABA receptor-
mediated inhibition. These hypotheses were tested in vitro using a rat hypothalamic explant 
paradigm. 
Subjects and Methods 
CASE REPORT 
This girl was born at term of a normal pregnancy as the first child of healthy unrelated parents. On 
the day of birth, severe hypotonia was apparent. Spontaneous movements were sparse, but 
reactions were excessive upon stimulation. On day 5, generalized seizures were treated with 
phenobarbital (3–5 mg/kg∙day) and phenytoin (5–10 mg/kg∙day). On day 10, NKH was diagnosed 
based on elevated glycine concentrations in plasma (1044 µmol/L; normal range, 80–340) and 
cerebrospinal fluid (112 µmol/L; normal, 3–12). The infant gradually developed severe lethargy, 
psychomotor retardation, and convulsions refractory to conventional antiepileptic therapy. 
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By 11 months of age, breast development was noticed and scored as stage M2–M3 according to 
Tanner (20). Height (81.4 cm) was above the 97th percentile for chronological age, and height 
velocity was rapid, as shown by the growth curve (Fig. 1). Head circumference was 45.5 cm (50th 
percentile). Bone age was advanced to 26 months according to the criteria of Tanner and 
Whitehouse (21). At 12 months, plasma LH was increased for age (9.7 mIU/mL; normal, < 2). FSH 
was slightly elevated (3.4 mIU/mL; normal, < 3). IGF-I was at the upper normal limit (112 µg/L; 
normal, 44–110). GH measured on two occasions (3.0 and 1.0 µg/L) as well as PRL (259 µU/mL) 
were not elevated. Sexual precocity of central origin was diagnosed, although no GnRH test was 
performed. 
Fig. 1. Length in relation to age and bone age (BA) in a girl with nonketotic hyperglycinemia. The Tanner 
stages of breast development (M) were estimated on three occasions, and basal plasma LH levels were 
determined on two occasions. The bars show the timing of administration of various antiepileptic drugs. 
 
 
The multiple daily seizure episodes did not respond to phenobarbital, which was discontinued at 
11 months. As only partial improvement was seen using phenytoin, treatment with loreclezole (1 
mg/kg∙day) was initiated. This new antiepileptic agent (Janssen Pharmaceutica, Beerse, Belgium) 
has a stimulatory action at a modulatory site distinct from the benzodiazepine site within the 
GABA-receptor complex (22). At 15 months of age, 4 months after starting loreclezole treatment, 
regression of breast development (M2) was noticed, and height velocity started to decrease (Fig. 1). 
Basal plasma LH was 2.6 mIU/mL. Loreclezole therapy only slightly decreased the frequency of 
seizure episodes and was discontinued at 22 months of age. Vigabatrin (Sabril, Marion Merrell Dow, 
Strasbourg, France; 30–70 mg/kg∙day), another GABA agonist acting through irreversible inhibition 
of GABA transaminase (23), was given from 19 months of age and had a significant anticonvulsive 
effect. At 24 months, further evidence of reduced growth velocity was obtained, breast 
development disappeared (M1), and bone age advancement decreased to 5 months compared to 
chronological age. After 27 months of age, a normal growth rate was observed (Fig. 1). Treatment 
using diazepam (1.5–3 mg/kg∙day) was started. At 4 yr of age, a computed tomographic scan of the 
brain visualized diffuse cortical and subcortical atrophy without any focal abnormality, particularly 
in the hypothalamopituitary area. 
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IN VITRO STUDIES 
Retrochiasmatic hypothalamic explants from 15-, 25-, or 50-day-old male rats were studied 
individually (12–15 explants/experiment) using a static incubation system (Fig. 2). The incubation 
medium (0.5 mL) was renewed every 7.5 min for 3–5 h, and the collected fractions were kept frozen 
until assayed for GnRH using a highly sensitive RIA. This procedure has been described in detail 
previously (5, 6). It is of note that the studied explants did not include the preoptic area where the 
perikarya of GnRH neurons are located in the rat brain. We confirmed recently that most of the 
studied explants contained no GnRH cell bodies, in contrast to the 200–400 perikarya visualized in 
the preoptic area (24). 
Fig. 2. Representative profile of pulsatile GnRH secretion by individual explants of the retrochiasmatic 
hypothalamus from 15-, 25-, and 50-day-old male rats. The mean ± SD interpulse interval is given. The broken 
lines indicate the limit of detection of GnRH release. ●, Significant pulse (Pulsar program). 
 
 
Although the incubation medium contained 400 µmol/L glycine in our early experiments (2), a 
reduced concentration of 0.01 µmol/L was used subsequently because it resulted in optimal GnRH 
release in response to NMDA (25). The developmental changes in the frequency of pulsatile GnRH 
secretion have been characterized in medium containing 0.01 µmol/L glycine and correlated with 
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the occurrence of spermatids measured through flow cytometry in testicular homogenates, as 
described previously (3). Here, using explants of 15-day-old rats, we studied the effect of glycine 
concentration (0.0001–100 µmol/L) on the frequency of pulsatile GnRH secretion. These 
experiments were repeated using 7-chlorokynurenate (7CK), a specific antagonist of glycine 
binding at the NMDA-receptor complex (26), and strychnine, an antagonist at the non-NMDA 
glycine receptor in the CNS (27). Also, the effects of loreclezole and vigabatrin, two GABA agonists, 
were studied at 15 and 25 days. The significance of GnRH secretory pulses was determined using 
the Pulsar program (28), as described previously (3). The significance of changes in mean GnRH 
pulse frequency was calculated through ANOVA with correction for repeated measurements and by 
Scheffe’s F test (29). 
Results 
Using explants incubated with 0.01 µmol/L glycine, the frequency of pulsatile GnRH secretion was 
similar at 25 days, when spermatids started to occur, to that at 50 days, when they attained an 
adult level in the testis. In contrast, GnRH pulse frequency was lower at 15 days (Fig. 2), indicating 
that an acceleration of pulsatility precedes the onset of puberty, in agreement with our previous 
findings (3). When the hypothalamic explants of 15-day-old rats were incubated without glycine, no 
GnRH release could be detected at any time during a 3-h experiment. Therefore, the interval 
between GnRH secretory pulses, if any, should have been greater than 180 min under those 
conditions (Fig. 3A). When glycine concentrations of 0.0001, 0.001, and 0.01 µmol/L were used, 
GnRH release became detectable, and secretory pulses were seen. The mean GnRH interpulse 
interval decreased, in relation to the glycine concentration (Fig. 3, B and C), to a mean of 61 min, 
which was observed using 0.01 µmol/L glycine (Fig. 3D). Using 0.1 µmol/L glycine, an hourly 
interval was seen as well (Fig. 3E). A further increase in the glycine concentration resulted in more 
frequent GnRH pulses that occurred at a significantly shorter interval using 10 µmol/L glycine (Fig. 
3G) than using 0.1 µmol/L. Such an effect was not seen using 100 µmol/L glycine (Fig. 3H). 
When explants from 15-day-old animals were incubated using 0.01 µmol/L glycine (Fig. 4, upper 
panels), the addition of the glycine antagonists 7CK (Fig. 4B) and strychnine (Fig. 4C) or the GABA 
agonist loreclezole (Fig. 4D) failed to affect the frequency of pulsatile GnRH secretion. When 
incubation was performed in a high (10 µmol/L) glycine concentration (Fig. 4, lower panels), the 
interval between GnRH pulses was reduced (Fig. 4, E vs. A). The acceleration of pulsatility caused 
by 10 µmol/L glycine was prevented by 100 µmol/L 7CK (Fig. 4F) or 10 µmol/L loreclezole (Fig. 4H). 
Using 100 µmol/L strychnine, the glycine-induced acceleration of GnRH pulse frequency was 
partially inhibited (Fig. 4G). 
Using explants from 25-day-old rats under control conditions, the interpulse interval of GnRH 
secretion was shorter than that at 15 days (Table 1). Using explants from 25-day-old rats, 
loreclezole as well as vigabatrin increased the GnRH interpulse interval (Table 1); this was not the 
case for loreclezole using explants from 15-day-old animals (Fig. 4D). 
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Fig. 3. Effect of glycine concentration in incubation medium of retrochiasmatic hypothalamic explants of 15-
day-old male rats on the pulsatile secretion of GnRH. At each glycine concentration, a representative 
secretory profile of an individual explant and the mean (±SD) interval between GnRH pulses are shown. Four 
to six explants were studied in each condition. The asterisks denote a mean interval significantly different (P 
< 0.05) from that seen using 0.01 µmol/L glycine (A–D) or 0.1 µmol/L glycine (E–H). The broken lines indicate 
the limit of detection of GnRH release. ●, Significant pulse (Pulsar program). 
 
 
Fig. 4. Effect of the glycine antagonists 7CK and strychnine and the GABA agonist loreclezole on pulsatile 
GnRH secretion from retrochiasmatic hypothalamic explants of 15-day-old male rats incubated using low 
(0.01 µmol/L) or high (10 µmol/L) glycine concentrations. In each study condition, a representative secretory 
profile of an individual explant and the mean (±SD) interval between GnRH pulses are shown. Four to six 
explants are studied for each condition. The asterisks denote a significant difference (P < 0.05) between the 
mean intervals seen under control conditions and using the pharmacological glycine antagonists and GABA 
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Table 1. Effects of loreclezole and vigabatrin on the interval between GnRH pulses secreted by hypothalamic 
explants of 25- day-old male rats incubated using 0.01 µmol/L glycine. 
GABA agonists (10 µmol/L) GnRH interpulse interval (min) 
Control 39.6 ± 4.9 
Loreclezole 52.5 ± 3.5a 
Vigabatrin 48.8 ± 4.7a 
The data are the mean ± SD of the interval between GnRH pulses secreted by four to six individual rat 
hypothalamic explants in each group. 
a P < 0.05 compared to 25 day controls. 
Discussion 
The patient described has a neonatal form of NKH. This severe genetic disease results from an 
inherited defect in the enzymatic system cleaving glycine. In NKH, the cerebrospinal fluid 
concentrations of glycine are highly increased into a characteristic range of 83–280 µmol/L (30). 
Some NKH symptoms, such as hypotonia, involve the inhibitory strychnine-sensitive glycine 
receptors (30), whereas the pathogenesis of seizures involves the excitatory strychnine-insensitive 
glycine receptors belonging to the NMDA-receptor complex (31). In the reported girl, evidence of 
abnormal estrogenic effect starting early in postnatal life was provided by the acceleration of 
growth during the first year and the advancement of bone maturation. As commonly seen in 
female precocious puberty, breast tissue developed after growth acceleration. Although we have 
not documented the central origin of puberty through a GnRH test, basal LH was increased and 
later returned to normal when pubertal development regressed. CNS imaging did not show any 
anatomical abnormality in the hypothalamus or other regions known to be involved in the 
pathogenesis of precocious puberty. 
Based on the experimental induction of precocious puberty after chronic NMDA administration (11, 
12), the occurrence of precocious puberty in a patient with NKH was thought to result from 
excessive stimulation by glycine of the NMDA receptors linked to the GnRH neurons. The 
development of precocious puberty after NMDA receptor-mediated lesion of some neurons 
inhibitory to GnRH neurons cannot be ruled out. This hypothesis, however, is unlikely because 
neonatal overstimulation of glutamate receptors results in panhypopituitarism secondary to the 
loss of a majority of neurons in the arcuate nucleus (32), whereas there isno evidence of such 
deficiencies in our patient. Early sexual maturation has not been reported in NKH patients to date. 
It is possible that only some NKH patients have glycine concentrations that make them prone to 
early pubertal maturation. Indeed, only a particular range of glycine concentrations can potentiate 
the NMDA-evoked release of GnRH (25) and pulsatile GnRH secretion (this study), whereas such a 
potentiation is not observed using higher glycine concentrations. The concentrations of glycine 
commonly used for in vitro studies of hypothalamic explants are about 100–1000 times lower than 
CSF concentrations. The differences between in vitro and in vivo conditions make difficult any 
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comparison based on substrate concentrations, and interpretation of our data relies more on the 
relative changes in glycine concentration than on the absolute levels achieved. 
The symptoms of precocious puberty regressed and finally disappeared, whereas there was no 
change in the metabolic and neurological situation. Spontaneous regression, which is the usual 
outcome of premature thelarche, was unlikely to occur in central precocious puberty. Therefore, 
we postulated that changes in antiepileptic treatment could have interfered. This hypothesis is 
consistent with the pivotal role of the GABAA (ionotropic) receptors in the prepubertal inhibition of 
pulsatile GnRH secretion in the female monkey (15). The GABAA receptor is a heteromer of different 
subunits with distinct binding sites for GABA, anesthetic or sex steroids, barbiturates, and 
benzodiazepines (33). Therefore, the GABAA receptor can be targeted directly by some antiepileptic 
drugs such as barbiturates, benzodiazepines, and loreclezole (22), or indirectly by drugs such as 
vigabatrin (23) or sodium valproate (16), which reduce GABA degradation. The widespread use of 
different pharmacological GABA receptor agonists in NKH may be an additional reason why 
precocious puberty has not been commonly seen in those patients. The inhibition of pubertal 
development by GABA agonists in our patient is consistent with the inhibition of LH secretion by 
valproate seen in peripubertal subjects (17). In adult women, however, such an inhibition could not 
be observed (34, 35), in agreement with our finding that the GABA agonist muscimol and the 
antagonist bicuculline did not affect pulsatile GnRH secretion in the postpubertal rat 
hypothalamus at 50 days of age (14). These late developmental changes in GABA receptor-
mediated effects may be related to sex steroids, because acute inhibition of pulsatile LH secretion 
by valproate was found in postmenopausal women (19). 
As it was not ethically possible to evaluate the role of NMDA receptor-related glycine receptors and 
GABAA receptors in the affected child, we tested the proposed concept in a well characterized 
paradigm of rat hypothalamic explants. The immortalized GnRH neurons are an alternative 
contemporary model. However, developmental changes cannot be studied in these conditions 
using hypothalamic explants (2, 3). In addition, the retrochiasmatic hypothalamus appears to 
contain a pulse generator different from the GnRH neuron (24) and involving both the facilitatory 
NMDA component and the inhibitory GABAA component (13, 14), which are known to exist in the 
subhuman primate as well (12, 15). The glycine-dependent increase in the frequency of pulsatile 
GnRH secretion is mediated at the NMDA receptor, as this effect is prevented by 7CK, an antagonist 
specific for the glycine-binding site of the NMDA receptor complex (26). However, 100 µmol/L of the 
antagonist 7CK does not abolish pulsatile GnRH secretion. Using a higher 7CK concentration of 500 
µmol/L, which is able to completely suppress GnRH secretion evoked by NMDA (14), the frequency 
of pulsatile GnRH secretion is reduced, but the secretion is not suppressed, as seen in the absence 
of glycine. These data suggest that glycine may contribute to GnRH secretion through different 
mechanisms, one of which involves NMDA receptors. When glycine or normal development results 
in accelerated GnRH pulsatility, loreclezole or vigabatrin can restore a prepubertal pattern of 
pulsatile GnRH secretion. These findings are in agreement with the effects of bicuculline, a typical 
pharmacological antagonist of GABAA receptors (14, 15). 
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In summary, the premature development of puberty in a female infant with NKH and the 
regression of those manifestations during therapy with GABA agonists provide preliminary clinical 
evidence of involvement of NMDA and GABA receptors in the facilitatory and inhibitory control of 
the onset of human puberty. These data point to the pathophysiological importance of extensive 
evaluation of neuroendocrine function in NKH as well as in peripubertal patients treated with GABA 
agonists as antiepileptic agents. 
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